Studies have shown that targeted NBs can increase the peak time and intensity values of tumor imaging in vitro compared to nontargeted NBs.10, 11, 12 Prostate‐specific membrane antigen (PSMA), which was discovered in 1987, is a unique intact transmembrane type 2 glycoprotein in prostate epithelial cells.13 Its expression is positively correlated with the mortality rate of PCa14 and is considered the most important protein target in diagnostic‐specific immunolocalized imaging and immunoguided therapy.15, 16. The gene discussed is FOLH1; the disease is neoplasm.